Teleflex Incorporated is a global provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety, and reducing total procedural costs . The company primarily designs, develops, manufactures, and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications . Teleflex's product categories include vascular access, interventional, anesthesia, surgical, interventional urology, respiratory, and urology, with a significant portion of revenue coming from single-use medical devices .
- Vascular Access - Provides catheters and intraosseous access systems used in various critical care therapies.
- Interventional - Offers coronary catheters and structural heart support devices crucial for therapeutic procedures.
- Anesthesia - Includes airway management and pain management devices for surgical and critical care settings.
- Surgical - Comprises ligation clips and surgical instruments for various surgical applications.
- Interventional Urology - Features the UroLift System and Barrigel, a rectal spacing product, as key components.
- Respiratory - Supplies devices and systems for respiratory care and management.
- Urology - Provides a range of products for urological procedures and care.
- OEM Segment - Designs and supplies custom components for other medical device manufacturers, with revenue recognized over time due to the custom nature of the products.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Liam J. Kelly ExecutiveBoard | Chairman, President, and Chief Executive Officer | None | Liam J. Kelly joined Teleflex in June 2011 and has held various senior roles, becoming CEO in January 2018. He has been instrumental in the company's growth and operations. | View Report → |
Cameron P. Hicks Executive | Corporate Vice President, Human Resources and Communications | None | Cameron P. Hicks has been with Teleflex since April 2013, focusing on human resources and communications. | |
Daniel V. Logue Executive | Corporate Vice President, General Counsel, and Secretary | None | Daniel V. Logue joined Teleflex in June 2004 and has played a significant role in legal and compliance matters. | |
James Winters Executive | Corporate Vice President, Manufacturing and Supply Chain | None | James Winters joined Teleflex in March 2018 and has been critical in supply chain resilience and operational agility. | |
Jay White Executive | Corporate Vice President and President, Global Commercial | None | Jay White joined Teleflex in March 2005 and has contributed to growth and innovation across multiple business areas. | |
Thomas E. Powell Executive | Executive Vice President and Chief Financial Officer | None | Thomas E. Powell joined Teleflex in August 2011 and has overseen financial operations, ensuring compliance and presenting fair financial results. | |
Candace H. Duncan Board | Director | Director of Discover Financial Services | Candace H. Duncan has been a director since 2015, with a background in public accounting. | |
Gretchen R. Haggerty Board | Director | Director of Atmus Filtration Technologies Inc. and Johnson Controls International plc | Gretchen R. Haggerty has been a director since 2016, bringing financial expertise to the board. | |
Jaewon Ryu Board | Director | Director of Privia Health Group, Inc. | Jaewon Ryu, M.D., has been a director since 2023, with experience in healthcare delivery and legal aspects. | |
John C. Heinmiller Board | Director | Member of the board of directors of a hospital system | John C. Heinmiller has been a director since 2019, with extensive experience in financial oversight. | |
Stephen K. Klasko Board | Director | None | Stephen K. Klasko, M.D., has been a director since 2008, providing insights into healthcare trends and strategic initiatives. | |
Stuart A. Randle Board | Director | Director of Beacon Roofing Supply, Inc. and Comera Life Sciences Holdings, Inc. | Stuart A. Randle has been a director since 2009, with extensive experience in the medical device industry. |
-
Given the ongoing challenges with UroLift in the doctor's office setting and the reliance on Palette's Barrigel to achieve your interventional urology guidance, what specific strategies are you implementing to address UroLift's underperformance and stimulate growth in this segment?
-
With your recent share repurchase authorization alongside an active M&A pipeline, how are you balancing capital allocation between returning capital to shareholders and investing in growth opportunities, especially when considering potential dilution from acquisitions like Palette?
-
Regarding the anticipated increase in intra-aortic balloon pump sales due to your competitor's challenges, what measures are you taking to expand manufacturing capacity and secure long-term customer relationships, and how confident are you in the sustainability of this opportunity beyond the short term?
-
As you aim to capture additional market share in the intra-aortic balloon pump market without anticipating significant price increases, how do you plan to maintain or improve margins given existing pricing agreements and potential pricing pressures in a more concentrated market?
-
The reduction in your GAAP earnings per share guidance includes an increase in the restructuring line; can you provide more transparency on the restructuring activities driving this change and elaborate on any underlying factors that investors should be aware of?
Research analysts who have asked questions during Teleflex Inc earnings calls.
Anthony Petrone
Mizuho Financial Group
4 questions for TFX
Jayson Bedford
Raymond James
4 questions for TFX
Craig Bijou
Bank of America Securities
3 questions for TFX
Matthew O'Brien
Piper Sandler & Co.
3 questions for TFX
Michael Matson
Needham & Company
3 questions for TFX
Michael Polark
Wolfe Research, LLC
3 questions for TFX
Patrick Wood
Morgan Stanley
3 questions for TFX
Richard Newitter
Truist Securities
3 questions for TFX
Shagun Singh Chadha
RBC Capital Markets
3 questions for TFX
Larry Biegelsen
Wells Fargo & Company
2 questions for TFX
David Turkaly
Citizens JMP
1 question for TFX
Kristen Stewart
CL King & Associates
1 question for TFX
Matthew Taylor
Jefferies
1 question for TFX
Matt Taylor
Jefferies & Company Inc.
1 question for TFX
Michael Sarcone
Jefferies
1 question for TFX
Mike Matson
Needham & Company
1 question for TFX
Mike Polark
Wolfe Research, LLC
1 question for TFX
Ravi Misra
Truist Securities
1 question for TFX
Shagun Singh
RBC Capital Markets
1 question for TFX
Unknown
Piper Sandler
1 question for TFX
Vikramjeet Chopra
Wells Fargo & Company
1 question for TFX
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Palette Life Sciences AB | 2024 | Teleflex acquired Palette Life Sciences AB with an initial cash payment of $594.9 million and up to $50 million in contingent payments linked to net sales growth, strategically complementing its interventional urology portfolio with hyaluronic acid gel-based products. Integration efforts—including employee onboarding and IT integration—were well underway in 2024, with improved revenue guidance noted. |
Standard Bariatrics, Inc. | 2022 | Completed on September 27, 2022, Teleflex’s acquisition involved a $170 million upfront cash payment and potential additional payments up to $130 million based on milestone achievements; this deal, which brought the innovative Titan SGS Stapler into Teleflex’s surgical product portfolio, supports its strategic push into the sleeve gastrectomy market. |
Undisclosed Catheter Company | 2022 | In a deal finalized on June 13, 2022, Teleflex acquired a privately-owned catheter company for an initial payment of $22.8 million with up to $26.2 million in potential contingent payments, primarily securing a proprietary catheter design and related intellectual property to bolster its interventional product offerings. |
Recent press releases and 8-K filings for TFX.
- Teleflex Incorporated announced that its Barrigel™ rectal spacer is now available for purchase in Japan, following approval by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), insurance coverage acceptance, and issuance of appropriate use criteria by Japanese academic societies.
- Barrigel™ is the first sculptable non-animal stabilized hyaluronic acid (NASHA) rectal spacer proven to significantly reduce radiation to the rectum during prostate cancer radiotherapy and is indicated for T1–T3b disease.
- In a U.S. clinical study, 98% of men treated with Barrigel™ met the primary endpoint of ≥25% reduction in rectal radiation; patients averaged an 85% reduction in V54 Gy; and the device demonstrated superior reduction of acute and long-term Grade 1+ GI toxicity at 3 and 6 months versus control.
- The launch targets a significant market, with 104,318 new prostate cancer cases (representing 18% of all cancer diagnoses) reported in Japan in 2022, aligning with Teleflex’s global expansion strategy for Barrigel™.
- Teleflex-backed Keyron appointed David Feigal MD as Head of Regulatory Affairs, Joyce Peetermans, Ph.D. as Acting CTO, and Christopher Rowland as Chairman to steer its regulatory, clinical, and corporate development efforts.
- ForePass, Keyron’s fully removable, endoscopically implantable device, aims to replicate metabolic surgery benefits without incisions for patients with BMI ≥35 plus diabetes or BMI ≥40.
- Large-animal studies showed excellent safety, tolerability and strong efficacy on weight loss and insulin production, with upcoming head-to-head data indicating superiority over Semaglutide.
- Keyron is preparing for First-In-Human trials and global regulatory submissions following completion of long-term preclinical validation.
- Teleflex delivered Q2 revenues of $780.9 M, up 4.2% YoY on a GAAP basis and 1% on an adjusted constant currency basis, beating its guidance; adjusted EPS was $3.73, up 9.1% YoY.
- The company completed the acquisition of BioTronic’s Vascular Intervention business on June 30, expecting the combined interventional portfolio to generate over $800 M in annual revenues and to be modestly accretive to adjusted EPS.
- Teleflex updated its 2025 guidance to constant currency revenue growth of 7.7%–8.7%, GAAP revenue growth of 9%–10% (implying $3.322 B–$3.352 B) and adjusted EPS of $13.90–$14.30, reflecting the acquisition, lower tariff impact and an FX tailwind.
- The planned separation of Teleflex’s NewCo remains on track for mid-2026, while a potential sale process has advanced through preliminary buyer meetings to maximize shareholder value.
- On June 24, 2025, Teleflex entered into Amendment No. 2 to its Third Amended and Restated Credit Agreement, effective upon customary closing conditions.
- The amendment adds $200 million of delayed-draw term loan commitments, raising the Delayed Draw Term Loan Facility to $700 million to support the acquisition of MS Holding II SE’s Vascular Intervention business segment.
- All other material terms of the credit agreement remain unchanged; JPMorgan Chase, Bank of America, PNC, Wells Fargo and HSBC act as joint lead arrangers and bookrunners for the facility increase.
- Q1 2025 Performance: Revenues were $700.7 million (a 5% YoY decline) with GAAP diluted EPS at $2.07 and adjusted EPS at $2.91
- Guidance & Tariff Impact: Full-year GAAP revenue guidance raised to 1.28%-2.28% and GAAP diluted EPS guidance lowered to $6.51-$6.91 , while 2025 guidance now factors in a $55 million tariff headwind with revised adjusted EPS guidance of $13.20-$13.60
- Strategic Initiatives: The company plans to separate into two public entities and is exploring a parallel spin along with the potential sale of NewCo
- Accelerated Share Repurchase: Completed a $300 million accelerated share repurchase (2.2 million shares at an average of $135.23)
- Segment Highlights: Americas revenue reached $475.7 million; Vascular Access rose 1.9%, while Interventional Urology declined 10.7% YoY, with additional contributions from EMEA and Asia